Press Release - Published Clinical Study Shows Improved Liver Health a

Delta Nutrassentials today announced the publication of its clinical study "Effects of Essential AD2 Supplement on Blood Acetaldehyde Levels in Individuals Who Have Aldehyde Dehydrogenase (ALDH2) Deficiency" in the American Journal of Therapeutics. The study was authored by Dr. Ken Fujioka, Director of Metabolic Research for Scripps Clinic in La Jolla, California, and Spencer Gordon, Founder of Delta Nutrassentials and graduate of U.C. Berkeley in Molecular Environmental Biology. The research was conducted by a third-party clinical research organization in Los Angeles, California.

One billion people globally have ALDH2 Deficiency, a genetic liver enzyme mutation that hinders the breakdown of acetaldehyde, a Group 1 toxic carcinogen. The clinical study results revealed two positive health impacts in ALDH2 Deficient participants who took the Essential AD2 supplement for 28 days:

44% reduction in aspartate transaminase (AST) and 37% reduction in alanine transaminase (ALT), both of which are indicators of liver damage and disease. Together, AST and ALT liver proteins are called the Liver Function Test and typically increase when there is liver damage.

49% decrease in blood acetaldehyde level from the lowest acetaldehyde measurement 20 minutes after consuming an amount of alcohol relative to body weight (2 standard alcoholic beverages for a person weighing 154 pounds) when compared to a placebo in the same individuals.

“Alcohol flush reaction is a sign that our liver enzymes cannot keep up with the acetaldehyde accumulating in our body when drinking alcohol. Essential AD2 helps reduce acetaldehyde in the bloodstream,” said Amy Chang, CEO of Delta Nutrassentials. “Even more compelling is the improvement in liver health we can enjoy from taking Essential AD2 on a daily basis, particularly for those of us who have ALDH2 Deficiency.”

40% of the East Asian population suffer from ALDH2 Deficiency, a genetic condition that is passed through the generations from parents to children. Exposure to acetaldehyde causes damage and inflammation, resulting in long-term negative health impacts for the group.

“We are constantly exposed to acetaldehyde in our modern environment through alcohol consumption, air pollution, cigarette smoke, and food and sugars. Scientific studies show that for the ALDH2 Deficient population, long term exposure even at low concentrations can result in higher rates of gastrointestinal cancers, liver cirrhosis, osteoporosis, and Alzheimer’s,” said Dr. Ken Fujioka, M.D., Lead Author of the clinical study, and Scientific Advisor of Delta Nutrassentials.

Essential AD2 is the first clinically-tested, daily health product designed to alleviate acetaldehyde accumulation in people with ALDH2 Deficiency worldwide. Since launching Essential AD2, Delta Nutrassentials’ sales have spanned across more than 30 countries.

“Essential AD2’s patent-pending formulation helps the body target acetaldehyde breakdown in three ways: (1) boosting the activity of the ALDH2 enzyme, (2) counteracting the acetaldehyde toxin directly with antioxidants, and (3) clearing acetic acid from our body to increase the rate at which acetaldehyde can be metabolized,” added Spencer Gordon, Founder of Delta Nutrassentials.

About Delta Nutrassentials
Based in Nevada, Delta Nutrassentials is focused on improving liver health, especially in those with ALDH2 Deficiency. Our modern lifestyle and environment are disrupting our health, and longevity begins with a desire to realign our health to its natural state of well-being. Our products are manufactured in the USA using high quality, safe ingredients and processes aligned with the FDA’s Current Good Manufacturing Practices (CGMP). For more information, visit http://www.deltanutra.com.